Accelerate@Babraham is underpinned by a group of talented, highly experienced individuals whose collective motivation is to share their experiences to ensure our next generation of life science start-ups can learn from those that have ‘been there, done it’ before. They are all passionate about the sector, and unafraid to challenge and be challenged. Find out more about some of them here…
Khatereh Ahmadi has worked in the biotech/pharma industry for 15 years. Previous to her current role at MSD/Merck as Executive Director, she was a co-founder and CEO of reViral Ltd.
Lilian is Senior Director, New Ventures and Transactions lead for Neuroscience, at Johnson & Johnson Innovation.
Jelena is a geneticist and serial entrepreneur, passionate about the potential of biotechnology to improve patients' lives.
Ala is an Investment Associate at Ascension Life Fund, responsible for deal-flow, portfolio management and technical due diligence.
Nazira Amra is a trained physician and experienced pharmaceutical commercial leader who has spent the last 20+ years working at the intersection of both strategy and operations in pharma.
Bobby Anderson is a Vice President at Silicon Valley Bank in their Life Science and Healthcare practice.
Having completed my PhD in Biochemistry at Reading, I very quickly decided that research was not for me. I became a sales rep, where I met Chris Torrance just after he had started Horizon Discovery.
Sam Barker is the Business Development and Alliance Manager at PhoreMost Ltd. Sam joined PhoreMost in 2016 as a scientist in the drug discovery team.
Maina is an investor with a focus on early stage technology companies, specifically biotechnology and medical devices.
Keith joined STORM Therapeutics as CEO in January 2017. Prior to STORM, Keith was Chief Executive of Cancer Research Technology Ltd, the commercial arm of Cancer Research UK.
As Director of Limewash, a strategic marketing agency, Sarah helps clients understand their customers, propositions and processes better, before working with them to develop communications.
Brian is an experienced life sciences business leader with a strong track record of success in both strategy and execution.
Hugo works in the Commercial and Technology team of Taylor Vinters, a law firm focussed on the innovation economy and supporting entrepreneurial ventures.
Mary has a 25-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies.
Ann is Senior Director of New Ventures & Transactions for Infectious Disease and Vaccines (IDV) at Johnson & Johnson Innovation, London.
Jane has over 30 years’ experience in the life science industry across biotech, pharma and agrochemicals.
Cassie is an Investment Director with Parkwalk Advisors specialising in Healthcare and Life Sciences.
Daria Donati is leading the Cytiva and Bioprocess Business inorganic pipeline, driving growth through M&A and strategic investments for the bioprocess business.
Steve has over 20 years biotechnology and pharmaceutical industry experience in both business development and R&D. He is currently Senior Director of Business Development at Kymab.
Dr Sally-Ann Emmas
Sally-Ann has a passion for supporting life science innovation and joined the Medicines Discovery Catapult in 2021 to help SMEs identify opportunities, optimise resources and de-risk their programmes.
Laura is passionate about supporting life science innovation and connecting the early innovation ecosystem. She has a background in academia and experience in entrepreneurship and finance.
David is an Oxford-based life sciences angel investor. Since 2016 he has been focused on early-stage investing, managing the Arrowfield Capital syndicate.
Eliot has more than 25 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals.
Following an academic career at Cambridge University spanning 20 years, leading a world-renowned group, David joined Index Ventures.
Jeremy is a Senior Director in GSK R&D's Worldwide Business Development Team, with a focus on identifying and evaluating innovative emerging science, drugs and technologies.
Vishal Gulati is a venture partner at Draper Esprit a leading European venture capital firm. His investment interests include healthtech, omics and synthetic biology.
Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA and previously was the Chief Commercial Officer at Genomics England.
Serial Entrepreneur and Co-founder of Amadeus Capital Partners, Dr Hermann Hauser KBE has wide experience in developing and financing companies in the information technology sector.
Miao focuses on early stage ventures in biotechnology and life sciences. She is an investment professional at Luminous Ventures, a UK-based venture capital firm focusing on human health and deep tech
David Holbrook is a qualified physician who has spent thirty-five years in medicine and medical innovation, and the last twenty in life sciences spinout investing, principally from academia.
Jackie Hunter is currently a Board Director of BenevolentAI, a UK unicorn company that uses artificial intelligence to disrupt the drug discovery and development process.
Steve Jackson FRS, FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute.
Stewart joined Crescendo in 2019 as Chief Business Officer and has over 20 years’ experience in business development.
Michael is a Health Innovation Lead at Innovate UK and responsible for the Biomedical Catalyst grant funding programme that supports UK life science SMEs.
Mark has worked in a range of business consulting roles and biotech companies, including a UCL spin out.
Pablo focuses on biotechnology and healthcare ventures. Previously, Pablo was an Investment Manager at Midven, a UK based early-stage biotech fund.
Tim Luker is currently VP External Innovation at Eli Lilly. He leads Lilly's external advancing innovation process within Global Corporate Business Development.
Allan Marchington is a founder and Managing Partner at Bridge Valley Ventures a UK based Life Science investor which was established by LifeArc of the UK leading medical charities.
As Head of Life Science Investment within the Life Sciences team at Cambridge Enterprise Christine focuses on drug discovery and is responsible for a broad portfolio.
Jolyon is co-founder and Head of Business Development at PetMedix, a Cambridge-based biopharmaceutical company developing antibody-based therapeutics for companion animals.
Jonathan Milner is an experienced entrepreneur and investor who is passionate about supporting UK life science and high-tech start-ups.
Tim is the inaugural Dr John C Taylor Professor of Innovation at the University of Cambridge, Head of the Institute for Manufacturing and Head of the IfM’s Centre for Technology Management.
Mariam is a Business Psychologist Consultant at OE Cam, focusing on the assessment and development of individuals and teams.
Kate is a Management Consultant in the life sciences Industry specialised in helping companies implement strategy through the development of capabilities and positive engagement.
Rabab Nasrallah is an investment professional with Earlybird Venture Capital based in Germany.
Natalia Novac is a part of the Emerging Technology and Innovation Group and is responsible for search and evaluation of novel healthcare technologies across all Eli Lilly indications in Europe.
Jane was an early employee of Cambridge Antibody Technology, which became MedImmune, the global biologics research and development arm of AstraZeneca.
Peju has worked in the clinical research industry for over 15 years during which she has acquired wide-ranging experience.
Jo Parfrey is an experienced and successful investment professional with more than 10 years in the private equity industry.
Pierre has over ten years of experience in Marketing, Communications and Sales in the Life Science sector, built up across a range of businesses.
Chris has over 25 years’ experience in finance, holding senior positions at a variety of organisation types mostly ranging from business start-ups through to mid-size.
Oli is an entrepreneur and deal maker with a track record in the early stage healthcare and life sciences sector.
In April 2013, Jill Reckless co-founded RxCelerate Ltd with David Grainger, an out-sourcing drug discovery and development platform.
Andy Richards is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK.
Nicholas has over 18 years’ experience in finance, with significant experience advising a wide variety of organisations, ranging from small start-ups through to large multinational organisations.
Nick is the Group CFO of RxCelerate and managing director of its Cambridge Partnership subsidiary.
With an HR background gained in various drug discovery organisations, Anne joined Mission Therapeutics in 2016 as Vice President, Human Resources.
Dr Rebecca Todd is an Investment Director with Longwall Ventures managing early stage investments in health tech and life sciences companies.
Neil is an experienced biotechnology professional with over 15 years of research and management experience in the biotechnology industry.
Dr Chris Torrance is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing.
Scientist, serial entrepreneur, accomplished C-suite executive, data strategist, mentor/coach and investor with decades of experience in life sciences, more specifically in genomics, and digital fields.
Malti B Vaghela
Malti is a Consultant at Boston Consulting Group (BCG), a global management consulting firm, with a particular focus on Healthcare.
Paul has over 25 years’ leadership experience in business development. Currently he is CBO for Mission Therapeutics, located on the Babraham Research Campus.
David is an Associate Director in AstraZeneca’s Emerging Innovations Unit, where he is responsible for driving entrepreneurial activities and identifying game-changing technologies.
Anna Williamson is a Director of Business Development at Roche Pharma Partnering and the Head of Roche’s Cambridge Innovation Hub providing business development support.